These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2959204)

  • 1. [Hormone dependency and progestogen therapy in the treatment of endometrial cancer].
    Okada H; Nakata Y; Fujimoto J; Fujita H
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2837-44. PubMed ID: 2959204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
    Okada H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of antitumoral activity of medroxyprogesterone acetate for endometrial cancer.
    Fujimoto J; Fujita H; Hosoda S; Okada H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1836-40. PubMed ID: 2531782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L
    Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
    Szarvas Z; Zsolnai B
    Acta Chir Hung; 1984; 25(4):269-76. PubMed ID: 6240879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Growth of endometrial cancer and hormone].
    Kanoh H; Hosono T; Matsui Y; Okudaira Y
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3696-703. PubMed ID: 2531993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies of the effect on the in vitro growth of endometrial cancers of hydroxyprogesterone caproate, norethisterone acetate and D-norgestrel].
    Schindler C; Rodriguez L
    Zentralbl Gynakol; 1984; 106(7):463-6. PubMed ID: 6730768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of advanced endometrial cancer].
    Okada H; Yamamoto T
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1848-55. PubMed ID: 2144105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormone therapy--recent advances].
    Matsumoto K; Noguchi S
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2816-23. PubMed ID: 2959202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate.
    Grenman SE; Roberts JA; England BG; Grönroos M; Carey TE
    Gynecol Oncol; 1988 Jun; 30(2):239-50. PubMed ID: 2967231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nude mouse system in the study of tumor biology, treatment strategies and progesterone receptor physiology in human endometrial carcinoma.
    Satyaswaroop PG; Zaino R; Clarke CL; Mortel R
    J Steroid Biochem; 1987; 27(1-3):431-8. PubMed ID: 2961935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oxyprogesterone caproate, tamoxifen and their combination on the level of steroid hormone receptors in the tumor, and some parameters of the reproductive system in patients with endometrial cancer.
    Vishnevsky AS; Shtofmakher JA; Bokhman JV; Tsyrlina EV; Bobrov JF; Chepick OF; Sofroniy DF
    Clin Exp Obstet Gynecol; 1990; 17(3-4):159-62. PubMed ID: 2127240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of progestin therapy on the level of cytoplasmic receptors in patients with cancer of the corpus uteri].
    Vishnevskiĭ AS; Bokhman IaV; Tsyrlina EV; Bobrov IuF; Fel'dkoren BI
    Vopr Onkol; 1989; 35(5):594-8. PubMed ID: 2545046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of progestational agents for postmenopausal hot flushes.
    Roopnarinesingh S
    Int J Gynaecol Obstet; 1982 Apr; 20(2):133-5. PubMed ID: 6125433
    [No Abstract]   [Full Text] [Related]  

  • 16. Progestational agents in advanced breast cancer: an overview.
    Haller DG; Glick JH
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):2-8. PubMed ID: 3026051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
    Bonte J
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):335-41. PubMed ID: 6526120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
    Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ; Zhang XY
    Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.